BAX - Baxter International Stock Price, News & Analysis

$64.04 -0.21 (-0.33 %)
(As of 11/23/2017 04:00 PM ET)
Previous Close$64.25
Today's Range$63.82 - $64.61
52-Week Range$43.13 - $65.70
Volume1.55 million shs
Average Volume2.68 million shs
Market Capitalization$35.01 billion
P/E Ratio26.55
Dividend Yield1.00%
Beta0.68

About Baxter International (NYSE:BAX)

Baxter International logoBaxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.


Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BAX
CUSIP07181310

Debt

Debt-to-Equity Ratio0.37%
Current Ratio2.80%
Quick Ratio2.22%

Price-To-Earnings

Trailing P/E Ratio26.55
Forward P/E Ratio26.35
P/E Growth2.15

Sales & Book Value

Annual Sales$10.16 billion
Price / Sales3.43
Cash Flow$3.44 per share
Price / Cash18.61
Book Value$17.36 per share
Price / Book3.69

Dividend

Annual Dividend$0.64
Dividend Yield1.0%

Profitability

Trailing EPS$1.86
Net Income$4.97 billion
Net Margins9.88%
Return on Equity15.00%
Return on Assets8.12%

Miscellaneous

Employees48,000
Outstanding Shares544,830,000

Frequently Asked Questions for Baxter International (NYSE:BAX)

What is Baxter International's stock symbol?

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

How often does Baxter International pay dividends? What is the dividend yield for Baxter International?

Baxter International declared a quarterly dividend on Tuesday, November 14th. Investors of record on Friday, December 1st will be given a dividend of $0.16 per share on Tuesday, January 2nd. This represents a $0.64 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, November 30th. View Baxter International's Dividend History.

How were Baxter International's earnings last quarter?

Baxter International Inc. (NYSE:BAX) released its earnings results on Wednesday, October, 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05. The medical instruments supplier earned $2.71 billion during the quarter, compared to the consensus estimate of $2.66 billion. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The business's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.56 EPS. View Baxter International's Earnings History.

When will Baxter International make its next earnings announcement?

Baxter International is scheduled to release their next quarterly earnings announcement on Tuesday, January, 30th 2018. View Earnings Estimates for Baxter International.

What guidance has Baxter International issued on next quarter's earnings?

Baxter International issued an update on its fourth quarter earnings guidance on Wednesday, October, 25th. The company provided earnings per share (EPS) guidance of $0.56-0.59 for the period, compared to the Thomson Reuters consensus estimate of $0.60.

Where is Baxter International's stock going? Where will Baxter International's stock price be in 2017?

12 equities research analysts have issued 1-year price objectives for Baxter International's shares. Their predictions range from $60.00 to $75.00. On average, they expect Baxter International's share price to reach $67.55 in the next year. View Analyst Ratings for Baxter International.

What are Wall Street analysts saying about Baxter International stock?

Here are some recent quotes from research analysts about Baxter International stock:

  • 1. According to Zacks Investment Research, "Over the past year, Baxter has outperformed the broader industry in terms of price performance. The company rides on the recent launch of DeviceVue, a comprehensive asset tracking solution available exclusively to hospitals. However, lower cyclophosphamide sales in the coming quarters might mar the Baxter’s bottom line. Of the major positives, a favorable product mix, stringent cost control and expanding operating margin are notable. Baxter reported impressive results in the last quarter, driven by favorable tidings on the regulatory front, strategic partnerships and product launches. The company completed the acquisition of Claris Injectables in the recent past. Solid U.S. sales of IV therapies, IV access sets, select anesthesia and critical care products are key catalysts at the moment. On the flipside, a strong U.S. dollar, intensifying competition and lackluster sales growth are key concerns at the moment." (10/24/2017)
  • 2. UBS Group AG analysts commented, "Management delivered a solid 7c beat to our EPS estimate (+5c to consensus) driven by Fluid Systems (+$32 mil) and roughly in-line revenues across other major business lines. On the earnings line, higher sales net of COGS (+2c), lower SG&A spend (+8c) and higher non-op income (+2c) were partially offset by higher R&D (-2c) and a higher tax rate (-3c) to deliver a 7c beat to our EPS estimate. We continue to view the Claris deal as a positive, and expect continued solid operating performance, backed up with patient and prudent strategic investment. We remain Neutral on BAX." (2/2/2017)
  • 3. Evercore ISI analysts commented, "BAX reported a solid finish to the year, beating consensus EPS estimates by double digits and initiating above ST EPS guidance. There were several highlights in the 4Q print, both on the topline and operating metrics that made us incrementally more positive on our 'turnaround + long term EPS power underappreciated by Street' thesis. From a revenue perspective, Renal came in above, and management highlighted continued strong adoption of AMIA PD with patient volumes doubling past few Qs (AMIA will be a key long term driver, and these trends bode well). While management guided to 3-4% growth for Renal in FY17, we think the low end of the guidance seems conservative given strength in underlying business + AMIA uptake. Within Fluid Systems, yet another strong high single digit showing highlighted the strength of Sigma Spectrum pump uptake. We found it interesting that guidance assumes 'flattening of Sigma pump in 2017', which we think is a conservative assumption (competitor BDX still expects pump share gains in FY17). Overall, the constant currency growth of ~2% seems conservative, with potential upside in the event of lack of competitive entrants for cyclo business. On the margin front, while FY17 OM of ~15% seems optically below the ~15.7% seen in 2H'16 levels (but equates to an expansion of ~150 bps over FY16), we note that it contemplates about 150 bps of headwinds related to cyclo competition, Fx & TSA rolling off. As such, the ~15% OM guidance seems prudent to us, with possible upside tied to lack of competitive cyclo entrants. Finally, the EPS guide of $2.10-2.18 does not assume any share repo and no contribution from Claris. In light of the impressive free cash increase (FY16 FCF came in 80% above original guidance; FY17 guide of >$1 Bn) and ~$1 Bn of repatriation, we see upside potential to EPS upside tied to capital deployment. All in, this was a solid print, and current levels provide a good entry point for long term holders (we note BAX repurchased $250 MM worth of shares at an avg. of $47.50 in 4Q, which is around current trading levels)." (2/1/2017)

Who are some of Baxter International's key competitors?

Who are Baxter International's key executives?

Baxter International's management team includes the folowing people:

  • Jose E. Almeida, Chairman of the Board, President, Chief Executive Officer (Age 54)
  • James K. Saccaro, Corporate Vice President and Chief Financial Officer (Age 44)
  • Giuseppe Accogli, Senior Vice President, President - Global Businesses (Age 46)
  • Brik V. Eyre, Senior Vice President, President - Americas (Age 53)
  • Marcus Schabacker M.D. Ph.D., Chief Scientific Officer, Corporate Vice President (Age 53)
  • Scott Pleau, Corporate Vice President - Operations (Age 51)
  • Sean Martin, Corporate Vice President, General Counsel
  • Jeanne K. Mason Ph.D., Corporate Vice President - Human Resources (Age 61)
  • Paul Vibert, Corporate Vice President, President - International (Age 57)
  • Thomas T. Stallkamp, Lead Independent Director (Age 70)

Who owns Baxter International stock?

Baxter International's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Veritas Asset Management LLP (1.85%), Ameriprise Financial Inc. (1.50%), Bank of New York Mellon Corp (0.91%), Bessemer Group Inc. (0.87%), New York State Common Retirement Fund (0.30%) and Russell Investments Group Ltd. (0.29%). Company insiders that own Baxter International stock include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, John D Forsyth, Jose E Almeida, Kornelis J Storm, Peter S Hellman, Third Point Llc and Thomas T Stallkamp. View Institutional Ownership Trends for Baxter International.

Who sold Baxter International stock? Who is selling Baxter International stock?

Baxter International's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Marathon Asset Management LLP, Systematic Financial Management LP, Ameriprise Financial Inc., Smith Asset Management Group LP, New York State Common Retirement Fund, Sumitomo Mitsui Trust Holdings Inc. and Decatur Capital Management Inc.. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, John D Forsyth, Peter S Hellman, Third Point Llc and Thomas T Stallkamp. View Insider Buying and Selling for Baxter International.

Who bought Baxter International stock? Who is buying Baxter International stock?

Baxter International's stock was purchased by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Segall Bryant & Hamill LLC, Nordea Investment Management AB, SG Americas Securities LLC, Colony Group LLC, L & S Advisors Inc, Meag Munich Ergo Kapitalanlagegesellschaft MBH and Madison Investment Holdings Inc.. View Insider Buying and Selling for Baxter International.

How do I buy Baxter International stock?

Shares of Baxter International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Baxter International's stock price today?

One share of Baxter International stock can currently be purchased for approximately $64.04.

How big of a company is Baxter International?

Baxter International has a market capitalization of $35.01 billion and generates $10.16 billion in revenue each year. The medical instruments supplier earns $4.97 billion in net income (profit) each year or $1.86 on an earnings per share basis. Baxter International employs 48,000 workers across the globe.

How can I contact Baxter International?

Baxter International's mailing address is One Baxter Parkway, DEERFIELD IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]


MarketBeat Community Rating for Baxter International (BAX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  457 (Vote Outperform)
Underperform Votes:  395 (Vote Underperform)
Total Votes:  852
MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Baxter International (NYSE:BAX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 6 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $67.55 (5.47% upside)

Consensus Price Target History for Baxter International (NYSE:BAX)

Price Target History for Baxter International (NYSE:BAX)

Analysts' Ratings History for Baxter International (NYSE:BAX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/22/2017Bank of America CorporationReiterated RatingHoldN/AView Rating Details
11/22/2017Royal Bank Of CanadaReiterated RatingHold$66.00N/AView Rating Details
10/26/2017Stifel NicolausReiterated RatingHold$65.00N/AView Rating Details
10/26/2017Barclays PLCBoost Price TargetOverweight$70.00 -> $73.00N/AView Rating Details
10/26/2017Morgan StanleyBoost Price TargetEqual Weight$59.00 -> $62.00N/AView Rating Details
10/15/2017Cowen and CompanySet Price TargetHold$68.00N/AView Rating Details
10/13/2017BMO Capital MarketsReiterated RatingBuy$70.00N/AView Rating Details
8/17/2017Citigroup Inc.Initiated CoverageNeutral -> Neutral$63.00LowView Rating Details
7/27/2017Leerink SwannReiterated RatingOutperform$67.00 -> $75.00LowView Rating Details
7/26/2017Cantor FitzgeraldSet Price TargetBuy$70.00MediumView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy$71.00HighView Rating Details
4/29/2017Evercore ISIReiterated RatingOutperform$57.00 -> $60.00LowView Rating Details
10/13/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
8/15/2016ArgusReiterated RatingHoldN/AView Rating Details
7/27/2016J P Morgan Chase & CoBoost Price TargetNeutral$45.00 -> $48.00N/AView Rating Details
6/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$60.00N/AView Rating Details
5/10/2016Credit Suisse GroupReiterated RatingHoldN/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Baxter International (NYSE:BAX)

Earnings by Quarter for Baxter International (NYSE:BAX)

Earnings History by Quarter for Baxter International (NYSE BAX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/30/2018$0.59N/AView Earnings Details
10/25/2017Q3 2017$0.59$0.64$2.66 billion$2.71 billionViewN/AView Earnings Details
7/26/2017Q2 2017$0.57$0.63$2.59 billion$2.61 billionViewN/AView Earnings Details
4/26/2017Q1 2017$0.51$0.58$2.43 billion$2.48 billionViewN/AView Earnings Details
2/1/2017Q416$0.52$0.57$2.65 billion$2.65 billionViewListenView Earnings Details
10/25/2016Q316$0.45$0.56$2.67 billion$2.56 billionViewListenView Earnings Details
7/26/2016Q216$0.40$0.46$2.51 billion$2.60 billionViewListenView Earnings Details
4/26/2016Q116$0.29$0.36$2.35 billion$2.40 billionViewListenView Earnings Details
2/2/2016Q415$0.32$0.43$2.55 billion$2.60 billionViewListenView Earnings Details
10/27/2015Q315$0.29$0.41$2.46 billion$2.49 billionViewListenView Earnings Details
7/29/2015Q215$0.94$1.00$2.40 billion$3.90 billionViewListenView Earnings Details
4/23/2015Q115$0.88$1.00$3.70 billion$3.76 billionViewListenView Earnings Details
1/29/2015Q414$1.31$1.34$4.37 billion$4.47 billionViewListenView Earnings Details
10/16/2014Q314$1.31$1.31$4.21 billion$4.20 billionViewListenView Earnings Details
7/17/2014Q214$1.21$1.26$4.12 billion$4.30 billionViewListenView Earnings Details
4/17/2014Q114$1.10$1.19$3.88 billion$3.95 billionViewListenView Earnings Details
1/23/2014Q413$1.25$1.26$4.25 billion$4.40 billionViewListenView Earnings Details
10/17/2013Q313$1.19$1.19$3.82 billion$3.80 billionViewListenView Earnings Details
7/18/2013Q2 2013$1.13$1.16$3.70 billion$3.67 billionViewListenView Earnings Details
4/18/2013Q1 2013$1.04$1.05$3.49 billion$3.45 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.26$1.26$3.72 billion$3.75 billionViewListenView Earnings Details
10/18/2012$1.14$1.14ViewN/AView Earnings Details
7/19/2012$1.11$1.12ViewN/AView Earnings Details
4/19/2012$1.00$1.01ViewN/AView Earnings Details
1/26/2012$1.17$1.17ViewN/AView Earnings Details
10/20/2011$1.08$1.09ViewN/AView Earnings Details
7/21/2011$1.02$1.07ViewN/AView Earnings Details
4/21/2011$0.93$0.98ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Baxter International (NYSE:BAX)
2017 EPS Consensus Estimate: $2.23
2018 EPS Consensus Estimate: $2.64
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.50$0.51$0.51
Q2 20172$0.55$0.56$0.56
Q3 20172$0.59$0.59$0.59
Q4 20172$0.58$0.58$0.58
Q1 20182$0.61$0.62$0.62
Q2 20182$0.66$0.67$0.67
Q3 20182$0.67$0.69$0.68
Q4 20182$0.67$0.69$0.68
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Baxter International (NYSE:BAX)

Next Dividend:1/2/2018
Annual Dividend:$0.64
Dividend Yield:1.00%
Dividend Growth:-36.10% (3 Year Average)
Payout Ratio:34.41% (Trailing 12 Months of Earnings)
26.34% (Based on This Year's Estimates)
23.70% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Baxter International (NYSE:BAX)

Dividend History by Quarter for Baxter International (NYSE BAX)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/14/2017quarterly$0.160.99%11/30/201712/1/20171/2/2018
7/18/2017quarterly$0.161.03%8/30/20179/1/201710/2/2017
5/2/2017quarterly$0.161.14%5/31/20176/2/20177/3/2017
2/21/2017quarterly$0.131.04%3/1/20173/3/20174/3/2017
11/8/2016quarterly$0.131.12%11/30/201612/2/20161/3/2017
7/19/2016quarterly$0.131.11%8/31/20169/2/201610/3/2016
5/3/2016quarterly$0.131.15%6/1/20166/3/20167/1/2016
2/16/2016quarterly$0.121.23%3/2/20163/4/20164/1/2016
11/11/2015quarterly$0.121.21%12/2/201512/4/20151/4/2016
7/29/2015quarterly$0.121.15%9/2/20159/4/201510/1/2015
5/5/2015quarterly$0.523.02%5/28/20156/1/20157/1/2015
2/17/2015quarterly$0.523.04%3/9/20153/11/20154/1/2015
11/11/2014quarterly$0.522.92%12/3/201412/5/20141/2/2015
7/22/2014quarterly$0.522.71%9/3/20149/5/201410/1/2014
5/5/2014quarterly$0.522.81%6/4/20146/6/20147/1/2014
2/18/2014quarterly$0.492.84%3/5/20143/7/20144/1/2014
11/12/2013quarterly$0.492.95%12/4/201312/6/20131/3/2014
7/23/2013quarterly$0.492.66%9/4/20139/6/201310/1/2013
5/6/2013quarterly$0.492.86%6/5/20136/7/20137/1/2013
2/19/2013quarterly$0.452.67%3/6/20133/8/20134/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Baxter International (NYSE BAX)

Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 83.49%
Insider Trades by Quarter for Baxter International (NYSE:BAX)
Insider Trades by Quarter for Baxter International (NYSE:BAX)

Insider Trades by Quarter for Baxter International (NYSE BAX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/6/2017Third Point LlcDirectorSell5,000,000$64.23$321,150,000.00View SEC Filing  
9/5/2017Thomas T StallkampDirectorSell8,920$62.28$555,537.60View SEC Filing  
8/25/2017John D ForsythDirectorSell9,440$61.76$583,014.40View SEC Filing  
8/24/2017Carole J ShapazianDirectorSell4,020$61.61$247,672.20View SEC Filing  
8/17/2017Giuseppe AccogliSVPSell12,670$60.96$772,363.20View SEC Filing  
5/23/2017Carole J ShapazianDirectorSell2,618$57.92$151,634.56View SEC Filing  
5/9/2017Carole J ShapazianDirectorSell3,760$55.89$210,146.40View SEC Filing  
5/8/2017Brik V EyreSVPSell130,732$55.69$7,280,465.08View SEC Filing  
4/10/2017Albert P L StrouckenDirectorSell4,280$52.80$225,984.00View SEC Filing  
3/29/2017James R Gavin IIIDirectorSell4,280$51.72$221,361.60View SEC Filing  
2/22/2017Peter S HellmanDirectorSell4,280$49.81$213,186.80View SEC Filing  
2/8/2017John D ForsythDirectorSell4,280$48.35$206,938.00View SEC Filing  
5/23/2016Jose E AlmeidaCEOBuy11,691$42.75$499,790.25View SEC Filing  
5/2/2016John D ForsythDirectorSell1,887$44.38$83,745.06View SEC Filing  
4/4/2016John D ForsythDirectorSell1,887$41.75$78,782.25View SEC Filing  
3/14/2016James R Gavin IIIDirectorSell5,660$40.34$228,324.40View SEC Filing  
2/17/2016Peter S. HellmanDirectorSell5,660$38.35$217,061.00View SEC Filing  
2/11/2016Kornelis J. StormDirectorSell5,660$35.98$203,646.80View SEC Filing  
5/22/2015Carole J ShapazianDirectorSell1,533$67.68$103,753.44View SEC Filing  
4/27/2015James R Gavin IIIDirectorSell4,830$71.06$343,219.80View SEC Filing  
7/25/2014Carole J ShapazianDirectorSell1,645$76.98$126,632.10View SEC Filing  
7/24/2014Thomas T StallkampDirectorSell8,300$76.82$637,606.00View SEC Filing  
7/9/2014Ludwig HantsonVPSell24,693$76.00$1,876,668.00View SEC Filing  
5/2/2014Carole ShapazianDirectorSell5,680$75.28$427,590.40View SEC Filing  
4/23/2014Kees StormDirectorSell5,760$72.45$417,312.00View SEC Filing  
4/21/2014Blake DevittDirectorSell4,334$73.12$316,902.08View SEC Filing  
3/27/2014Sebastian BufalinoVPSell21,600$75.10$1,622,160.00View SEC Filing  
9/12/2013Carole ShapazianDirectorSell1,941$71.58$138,936.78View SEC Filing  
8/1/2013Robert L Parkinson JrCEOSell725,750$73.33$53,219,247.50View SEC Filing  
7/26/2013David P ScharfVPSell55,438$73.79$4,090,770.02View SEC Filing  
7/25/2013James R Gavin IIIDirectorSell5,760$72.82$419,443.20View SEC Filing  
7/24/2013Carole J ShapazianDirectorSell4,320$73.58$317,865.60View SEC Filing  
7/22/2013Robert J HombachCFOSell47,452$73.95$3,509,075.40View SEC Filing  
7/16/2013Phillip L BatchelorVPSell5,850$73.00$427,050.00View SEC Filing  
5/22/2013Blake E DevittDirectorSell1,000$72.34$72,340.00View SEC Filing  
5/20/2013Sebastian J BufalinoVPSell24,000$73.75$1,770,000.00View SEC Filing  
5/17/2013Robert M DavisVPSell130,800$73.00$9,548,400.00View SEC Filing  
9/13/2012Michael J BaughmanVPSell11,500$61.00$701,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Baxter International (NYSE BAX)

Source:
DateHeadline
Baxter Internationals (BAX) Hold Rating Reaffirmed at Bank of America CorporationBaxter International's (BAX) Hold Rating Reaffirmed at Bank of America Corporation
www.americanbankingnews.com - November 23 at 3:18 PM
Baxter International (BAX) vs. STAAR Surgical (STAA) Head to Head ComparisonBaxter International (BAX) vs. STAAR Surgical (STAA) Head to Head Comparison
www.americanbankingnews.com - November 23 at 10:16 AM
Baxter International Sees Unusually Large Options Volume (BAX)Baxter International Sees Unusually Large Options Volume (BAX)
www.americanbankingnews.com - November 23 at 1:34 AM
Royal Bank Of Canada Raises Baxter International Inc. (BAX) Price Target to $66.00Royal Bank Of Canada Raises Baxter International Inc. (BAX) Price Target to $66.00
www.americanbankingnews.com - November 22 at 8:04 AM
Baxter Recognized as Military Friendly Employer for Commitment to Veterans - Business Wire (press release)Baxter Recognized as Military Friendly Employer for Commitment to Veterans - Business Wire (press release)
www.businesswire.com - November 21 at 9:55 PM
Baxter International (BAX) a Strong Buy on High-Level Earnings Momentum - Investorplace.comBaxter International (BAX) a Strong Buy on High-Level Earnings Momentum - Investorplace.com
investorplace.com - November 21 at 9:55 PM
Baxter International (BAX) a Strong Buy on High-Level Earnings MomentumBaxter International (BAX) a Strong Buy on High-Level Earnings Momentum
investorplace.com - November 21 at 12:06 PM
Facing Saline Shortage, FDA Prioritizes Some Puerto Rico PlantsFacing Saline Shortage, FDA Prioritizes Some Puerto Rico Plants
finance.yahoo.com - November 17 at 3:10 PM
$2.76 Billion in Sales Expected for Baxter International Inc. (BAX) This Quarter$2.76 Billion in Sales Expected for Baxter International Inc. (BAX) This Quarter
www.americanbankingnews.com - November 17 at 2:38 AM
Trump Focuses on APAC: 4 MedTech Stocks to WatchTrump Focuses on APAC: 4 MedTech Stocks to Watch
finance.yahoo.com - November 16 at 4:40 PM
Billionaire Dan Loeb Upped Alibaba, Trimmed Google: 13F FilingBillionaire Dan Loeb Upped Alibaba, Trimmed Google: 13F Filing
finance.yahoo.com - November 16 at 11:48 AM
How Did the Dividend Cut Affect BAX’s Dividend Yield?How Did the Dividend Cut Affect BAX’s Dividend Yield?
finance.yahoo.com - November 16 at 11:48 AM
Baxter International Inc. (BAX) Expected to Announce Earnings of $0.59 Per ShareBaxter International Inc. (BAX) Expected to Announce Earnings of $0.59 Per Share
www.americanbankingnews.com - November 15 at 9:10 PM
US Hospitals Face a Shortage of This Most Basic Necessity - BloombergUS Hospitals Face a Shortage of This Most Basic Necessity - Bloomberg
www.bloomberg.com - November 14 at 4:53 PM
Baxter to Present at the Piper Jaffray Healthcare ConferenceBaxter to Present at the Piper Jaffray Healthcare Conference
finance.yahoo.com - November 14 at 4:53 PM
Best-in-Class Earnings Visibility Makes Baxter International (BAX) a Strong BuyBest-in-Class Earnings Visibility Makes Baxter International (BAX) a Strong Buy
investorplace.com - November 14 at 11:54 AM
Baxter International Inc. (BAX) Announces $0.16 Quarterly DividendBaxter International Inc. (BAX) Announces $0.16 Quarterly Dividend
www.americanbankingnews.com - November 14 at 9:56 AM
Global Surgical Sealants and Adhesives Market Share will Increase more than US$ 3 Billion By 2022Global Surgical Sealants and Adhesives Market Share will Increase more than US$ 3 Billion By 2022
www.marketwatch.com - November 14 at 1:35 AM
Earnings Review and Free Research Report: Baxter’s Revenue Grew 6%; EPS Rocketed 96%Earnings Review and Free Research Report: Baxter’s Revenue Grew 6%; EPS Rocketed 96%
finance.yahoo.com - November 14 at 1:35 AM
Baxter Posts Solid Q3, Broad Product Spectrum Raises Hopes - NasdaqBaxter Posts Solid Q3, Broad Product Spectrum Raises Hopes - Nasdaq
www.nasdaq.com - November 9 at 3:53 PM
Baxter Receives Perfect Score from Human Rights Campaign Foundation for Best Place to Work for LGBTQ Equality - Business Wire (press release)Baxter Receives Perfect Score from Human Rights Campaign Foundation for Best Place to Work for LGBTQ Equality - Business Wire (press release)
www.businesswire.com - November 9 at 3:53 PM
Stocks Showing Rising Market Leadership: Baxter International Earns 83 RS RatingStocks Showing Rising Market Leadership: Baxter International Earns 83 RS Rating
finance.yahoo.com - November 9 at 3:53 PM
Baxter Posts Solid Q3, Broad Product Spectrum Raises HopesBaxter Posts Solid Q3, Broad Product Spectrum Raises Hopes
finance.yahoo.com - November 9 at 3:52 PM
Baxter Receives Perfect Score from Human Rights Campaign Foundation for Best Place to Work for LGBTQ EqualityBaxter Receives Perfect Score from Human Rights Campaign Foundation for Best Place to Work for LGBTQ Equality
finance.yahoo.com - November 9 at 3:52 PM
ETFs with exposure to Baxter International, Inc. : November 9, 2017ETFs with exposure to Baxter International, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 3:52 PM
Baxter (BAX) Presents At Credit Suisse 26th Annual Healthcare Conference - SlideshowBaxter (BAX) Presents At Credit Suisse 26th Annual Healthcare Conference - Slideshow
seekingalpha.com - November 8 at 6:47 PM
Baxter International, Inc. :BAX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017Baxter International, Inc. :BAX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 6:47 PM
Baxter International (BAX) Shares Upgraded to Strong Buy - Investorplace.comBaxter International (BAX) Shares Upgraded to Strong Buy - Investorplace.com
investorplace.com - November 8 at 4:49 AM
Baxter Presents Data on the Role of SHARESOURCE Telehealth Platform in Helping the Clinical Management of Peritoneal Dialysis PatientsBaxter Presents Data on the Role of SHARESOURCE Telehealth Platform in Helping the Clinical Management of Peritoneal Dialysis Patients
finance.yahoo.com - November 7 at 6:44 PM
Baxter International Inc. (BAX) Director Third Point Llc Sells 5,000,000 SharesBaxter International Inc. (BAX) Director Third Point Llc Sells 5,000,000 Shares
www.americanbankingnews.com - November 7 at 6:28 PM
Baxter International (BAX) Shares Upgraded to Strong BuyBaxter International (BAX) Shares Upgraded to Strong Buy
investorplace.com - November 7 at 3:34 PM
Baxter International Inc. (BAX) Given Consensus Recommendation of "Buy" by AnalystsBaxter International Inc. (BAX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 5 at 9:32 AM
Baxter Supports 27 Abstract Presentations at ASN Kidney Week to Advance Scientific Exchange Focused on New ... - Business Wire (press release)Baxter Supports 27 Abstract Presentations at ASN Kidney Week to Advance Scientific Exchange Focused on New ... - Business Wire (press release)
www.businesswire.com - November 3 at 8:58 AM
Why Baxter’s Analysts Are Leaning toward a ‘Hold’Why Baxter’s Analysts Are Leaning toward a ‘Hold’
finance.yahoo.com - November 2 at 4:55 PM
Baxter Supports 27 Abstract Presentations at ASN Kidney Week to Advance Scientific Exchange Focused on New Standards of Renal CareBaxter Supports 27 Abstract Presentations at ASN Kidney Week to Advance Scientific Exchange Focused on New Standards of Renal Care
finance.yahoo.com - November 2 at 4:55 PM
Probing Baxter’s 3Q17 Earnings Growth: Key DriversProbing Baxter’s 3Q17 Earnings Growth: Key Drivers
finance.yahoo.com - November 1 at 5:01 PM
Probing Baxter’s 3Q17 Earnings Growth: Key DriversProbing Baxter’s 3Q17 Earnings Growth: Key Drivers
finance.yahoo.com - November 1 at 5:01 PM
Baxter Launches PD-First Program for Employees and FamiliesBaxter Launches PD-First Program for Employees and Families
finance.yahoo.com - November 1 at 5:01 PM
Baxter Launches PD-First Program for Employees and FamiliesBaxter Launches PD-First Program for Employees and Families
finance.yahoo.com - November 1 at 5:01 PM
Gauging Baxter’s Claris Acquisition Contribution to Its 3Q17 SalesGauging Baxter’s Claris Acquisition Contribution to Its 3Q17 Sales
finance.yahoo.com - November 1 at 5:01 PM
Gauging Baxter’s Claris Acquisition Contribution to Its 3Q17 SalesGauging Baxter’s Claris Acquisition Contribution to Its 3Q17 Sales
finance.yahoo.com - November 1 at 5:01 PM
Baxter International’s Latest Guidance for Fiscal 2017Baxter International’s Latest Guidance for Fiscal 2017
finance.yahoo.com - November 1 at 5:01 PM
Baxter International’s Latest Guidance for Fiscal 2017Baxter International’s Latest Guidance for Fiscal 2017
finance.yahoo.com - November 1 at 5:01 PM
Behind Baxter’s Strong 3Q17 Sales GrowthBehind Baxter’s Strong 3Q17 Sales Growth
finance.yahoo.com - October 31 at 10:36 PM
Earnings Growth Metrics Drive Baxter International (BAX) to Strong Buy - Investorplace.comEarnings Growth Metrics Drive Baxter International (BAX) to Strong Buy - Investorplace.com
investorplace.com - October 31 at 5:34 PM
Baxter Hit a 52-Week High on October 27Baxter Hit a 52-Week High on October 27
finance.yahoo.com - October 31 at 5:33 PM
Earnings Growth Metrics Drive Baxter International (BAX) to Strong BuyEarnings Growth Metrics Drive Baxter International (BAX) to Strong Buy
investorplace.com - October 31 at 11:39 AM
$2.74 Billion in Sales Expected for Baxter International Inc. (BAX) This Quarter$2.74 Billion in Sales Expected for Baxter International Inc. (BAX) This Quarter
www.americanbankingnews.com - October 28 at 8:38 AM
UPDATE 1-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane MariaUPDATE 1-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria
www.businessinsider.com - October 27 at 6:37 PM
Baxter International (BAX) vs. CONMED Corporation (CNMD) Critical SurveyBaxter International (BAX) vs. CONMED Corporation (CNMD) Critical Survey
www.americanbankingnews.com - October 27 at 1:24 PM

Social Media

Financials

Chart

Baxter International (NYSE BAX) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.